Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran

EAST HANOVER, N.J., Aug. 30, 2020 /PRNewswire/ -- Novartis today announced results from a post-hoc analysis of pooled data from the Phase III ORION-10 and -11 trials evaluating the individual responses of patients on low-density lipoprotein cholesterol (LDL-C) reduction with inclisiran, a...

from PR Newswire: https://ift.tt/3hLQqxq